Directed new share issue in Targovax ASA (NO) — NOK 101 million

Carnegie acted as joint bookrunner in the directed new share issue of 12,627,684 shares at a subscription price of NOK 8.0 per share. Targovax is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. January 2020.